A retrospective follow-up study of prolonged nucleos(t)ide analogue and interferon combination therapy in HBeAg-positive chronic hepatitis B patients

To investigate the efficacy of a 96-week course of nucleos(t)ide analogue and interferon (IFN) combination therapy for achieving seroconversion at 24 weeks after completion in patients with chronic hepatitis B (CHB). One-hundred-and-thirty-five CHB patients with positivity for hepatitis B e antigen...

Full description

Saved in:
Bibliographic Details
Published inZhonghua gan zang bing za zhi Vol. 21; no. 4; p. 267
Main Authors Yu, Shu-Li, Guo, Chao-Ying
Format Journal Article
LanguageChinese
Published China 01.04.2013
Subjects
Antiviral Agents - therapeutic use
Follow-Up Studies
Hepatitis B e Antigens - blood
Hepatitis B, Chronic - drug therapy
Humans
Retrospective Studies
Treatment Outcome
Online AccessGet more information

Cover

More Information
Summary:To investigate the efficacy of a 96-week course of nucleos(t)ide analogue and interferon (IFN) combination therapy for achieving seroconversion at 24 weeks after completion in patients with chronic hepatitis B (CHB). One-hundred-and-thirty-five CHB patients with positivity for hepatitis B e antigen (HBeAg) were recruited for study between January 2005 and December 2008. All patients were given a 96-week course of nucleos(t)ide analogue (lamivudine or adefovir dipivoxil) alone (monotherapy controls, n = 45) or in combination with IFN or Pegylated-IFN-alpha-2a (Peg-IFNa-2a) (n = 90). At treatment weeks 12, 24, 48, 72, and 96, and at 24 weeks after treatment completion, serum samples were collected from all patients for assessment of biochemical, virological and serological responses to treatment. The biochemical response was indicated by normalization of the alanine aminotransferase (ALT) level. The virologic response was indicated by a reduction in the hepatitis B virus (HBV) DNA level to less than 1000 copies
ISSN:1007-3418
DOI:10.3760/cma.j.issn.1007-3418.2013.04.007